Top

International Journal of Colorectal Disease

Published in:

01-11-2010 | Review

Population-based screening for colorectal cancer with faecal occult blood test—do we really have enough evidence?

Authors: Göran Ekelund, Jonas Manjer, Sophia Zackrisson

Published in: International Journal of Colorectal Disease | Issue 11/2010

Abstract

Introduction

Population-based randomised controlled trials (RCT) have shown that invitation to biennial screening with faecal occult blood testing (FOBT) during 10 or more years reduced colorectal cancer-specific mortality. These results have stimulated plans to introduce mass screening in various countries; however, none of these trials has been able to show any reduction of total mortality, which should be expected with reduced disease-specific mortality in a RCT.

Methods

The aim of this review is to analyse, in more detail, the findings in these trials. The results of the trials have, in this review, been systematised and discussed in the context of potential bias, validity and effectiveness.

Results

It is found that the reduced cancer-specific mortality is modest and that the clinical significance may be discussed. The number of persons needed to be invited for multiple screening rounds to avoid one death in colorectal cancer (CRC) is high, ranging from about 600 to 1,200. A remarkable finding is that only one fourth of the carcinomas in those invited to the screening were actually detected by this intervention. The absence of reduced total mortality in all series is a serious problem and evokes questions about the validity in determination of cause of death. None of these trials showed any effect on incidence of CRC by removal of precancerous adenomas.

Conclusions

It seems reasonable to conclude that the scientific evidence to support introduction of population-based screening programmes with FOBT appears not yet strong enough. In addition, harm/benefit and cost/effectiveness ratios are not well determined.

Muto T, Bussey HJ, Morson BC (1975) The evolution of cancer of the colon and rectum. Cancer 36:2251–2270PubMed

Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U (2007) Risk of progression of advanced adenomas to colorectal cancer by age and sex:estimtes based on 840,149 colonoscopies. Gut 56(11):1585–1589, Epub 2007 Jun 25CrossRefPubMed

Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J (2000) Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev 2000;(2):CD001216. Review. Update in: Cochrane Database Syst Rev 2007;(1):CD001216

Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007) Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 24(1):CD001216, Review. doi:10.1002/14651858.CD001216.pub2

West NJ, Boustière C, Fischbach W, Parente F, Leicester RJ (2009) Colorectal cancer screening in Europe: differences in approach; similar barriers to overcome. Int J Colorectal Dis 24:731–740, Review. Erratum in: Int J Colorectal Dis 2009;24:1365–1366CrossRefPubMed

Cooper GS, Doug Kou T (2008) Underuse of colorectal cancer screening in a cohort of Medicare beneficiaries. Cancer 112:293–299CrossRefPubMed

American Society of Colon and Rectal Surgeons ASCRS News (2009) www.fascrsnews.org. Summer p 7

Steinwachs D, Allen JD, Barlow WE, Duncan P, Egede LE, Friedman LS, Keating NL, Lave KJRL, LaVeist TA, Ness RB, Optican RJ, Vimig BA (2010) National Institutes of Health state-of-the-science conference statement: enhancing use and quality of colorectal cancer screening. Ann Internal Med 52(10):663–667

Holden DJ, Jonas DE, Porterfield DS, Reutland D, Harris R (2010) NIH conference. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann Internal Med 152:668–676

10.

Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328:1365–1371CrossRefPubMed

11.

Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472–1477CrossRefPubMed

12.

Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD (2002) Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50:840–844CrossRefPubMed

13.

Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467–1471CrossRefPubMed

14.

Jørgensen OD, Kronborg O, Fenger C (2002) A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50:29–32CrossRefPubMed

15.

Kronborg O, Jørgensen OD, Fenger C, Rasmussen M (2004) Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 39:846–851CrossRefPubMed

16.

Lindholm E, Brevinge H, Haglind E (2008) Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 95:1029–1036CrossRefPubMed

17.

Carlsson U, Ekelund G, Eriksson R, Fork T, Janzon L, Leandoer L, Lindström C, Trell E (1986) Evaluation of possibilities for mass screening for colorectal cancer with Hemoccult fecal blood test. Dis Colon Rectum 29:553–557CrossRefPubMed

18.

Black WC, Haggstrom DA, Welch HG (2002) All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94:167–173PubMed

19.

Moayyedi P, Achkar E (2006) Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. Am J Gastroenterol 101:380–384, reviewCrossRefPubMed

20.

Whynes DK, Neilson AR, Walker AR, Hardcastle JD (1998) Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ 7:21–29CrossRefPubMed

21.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ (2009) Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 101:1412–1422CrossRefPubMed

22.

Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981CrossRefPubMed

23.

Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M, Italian Multicentre Study Group (2001) Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 48:812–815CrossRefPubMed

24.

Jørgensen OD, Kronborg O, Fenger C, Rasmussen M (2007) Influence of long-term colonoscopic surveillance on incidence of colorectal cancer and death from the disease in patients with precursors (adenomas). Acta Oncol 46:355–360CrossRefPubMed

25.

Keen JD, Keen JE (2009) What is the point: will screening mammography save my life? BMC Med Inform Decis Mak 9:18CrossRefPubMed

26.

Jørgensen KJ, Gøtzsche PC (2009) Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339:b2587. doi:10.1136/bmj.b2587 CrossRefPubMed

27.

Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP (2006) Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 332:689–692CrossRefPubMed

28.

Jørgensen KJ, Zahl PH, Gøtzsche PC (2010) Breast cancer mortality in organized mammography screening in Denmark: comparative study. BMJ Mar 23(340):c1241. doi:10.1136/bmj.c1241 CrossRef

29.

Singh H, Turner D, Xue L (2006) Risk of developing colorectal cancer following a negative colonoscopy examination. JAMA 295(20):2366–2374CrossRefPubMed

30.

Müller AD, Sonnenberg A (1995) Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Internal Med 13(12):904–910

31.

Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomized controlled trial. The Lancet. doi:10.1016/50140-6736(10)60551-X, Published online 2010 April 28

32.

Brenner H, Haug U, Arndt V, Stegmaier C, Altenhofen L, Hoffmeister M (2010) Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 138(3):870–876, Epub 2009 Nov 10CrossRefPubMed

33.

Baxter NN, Rabeneck L (2010) Is the effectiveness of colonoscopy “Good Enough” for poulation-based screening? JNCI 102(2):70–71. doi:10.1093/jnci/djp469, EditorialPubMed

34.

Macari M, Bini EJ (2005) CT colonography: where have we been and where are we going? Radiology 237:819–833, ReviewCrossRefPubMed

Title: Population-based screening for colorectal cancer with faecal occult blood test—do we really have enough evidence?
Authors: Göran Ekelund
Jonas Manjer
Sophia Zackrisson
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 11/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-010-1027-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Population-based screening for colorectal cancer with faecal occult blood test—do we really have enough evidence?

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2010

Prospective randomized clinical trial assessing the efficacy of a short course of intravenously administered amoxicillin plus clavulanic acid followed by oral antibiotic in patients with uncomplicated acute diverticulitis

Long-term results of stapled transanal rectal resection (STARR) for obstructive defecation syndrome

The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese

Pathological examination of 12 regional lymph nodes and long-term survival in stages I–III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution

Rare malignant neuroendocrine transformation of a presacral teratoma in patient with currarino syndrome

γ-Catenin is an independent prognostic marker in early stage colorectal cancer